Replimune Group, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended September 30, 2023; filed November 7, 2023. Financial statements are unaudited. Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies; it has no approved products and has generated no product sales revenue.
Financial performance and position
| Metric | Three months ended September 30, 2023 | Six months ended September 30, 2023 | Prior-year comparison |
|---|---|---|---|
| Revenue from product sales | None | None | None |
| Research and development expense | $49.1 million | $89.5 million | $28.8 million and $58.3 million, respectively |
| Selling, general and administrative expense | $14.7 million | $29.9 million | $12.7 million and $24.1 million, respectively |
| Net loss | $60.0 million; $0.90 per share | $109.6 million; $1.65 per share | $43.1 million and $85.4 million; $0.79 and $1.57 per share, respectively |
| Net cash used in operating activities | Not stated separately | $92.2 million | $66.7 million for six months |
| Cash, cash equivalents and short-term investments | $496.8 million at September 30, 2023 | $583.4 million at March 31, 2023 |
At September 30, 2023, total assets were $562.4 million, current liabilities $39.8 million, and stockholders’ equity $465.2 million. Long-term debt was $29.2 million net of discount and issuance costs; stated principal was $30.5 million. Lease liabilities totaled $31.6 million. Short-term investments were $420.8 million and cash and cash equivalents were $76.0 million; restricted cash was $1.6 million. Operating margins are not meaningful given the absence of product revenue.
Changes versus the prior comparable periods
- Quarterly operating expenses rose $22.3 million to $63.8 million; six-month expenses rose $37.0 million to $119.5 million. The increase chiefly reflected expanded clinical development, manufacturing work, and personnel costs.
- Quarterly net loss increased $16.9 million; six-month net loss increased $24.2 million. Higher investment income partly offset operating losses: six-month investment income was $12.2 million versus $1.5 million a year earlier.
- Six-month operating cash use increased to $92.2 million from $66.7 million. Cash and investments declined by $86.6 million from March 31, 2023.
- Shares issued and outstanding were 59.1 million at September 30, compared with 56.7 million at March 31. The company reported no shares sold under its new $250 million at-the-market program during the quarter or six-month period.
Outlook, developments and risks
- Management expects existing cash and investments to fund operations into the second half of calendar 2025, based on its current plan and assumptions. The notes also state that resources are expected to cover at least 12 months from issuance of the financial statements. The company expects continuing losses and may need additional capital.
- Management expected CERPASS RP1/ cemiplimab data in early December 2023 and, if the primary analysis demonstrated overall clinical benefit, planned a BLA submission in Q2 2024. For the IGNYTE anti-PD-1-failed melanoma cohort, it expected an all-patient data snapshot in early December 2023 and planned a BLA submission in Q3 2024; these plans depend on trial results and regulatory discussions.
- RP2 and RP3 studies were advancing in colorectal cancer and hepatocellular carcinoma with Roche. A planned head-and-neck cancer study with BMS was on hold because of shortages of cisplatin and carboplatin. Replimune also entered a 2023 collaboration with Incyte for an RP1 study; no related costs or payments were recorded through September 30.
- The Framingham manufacturing facility was described as operational; manufacturing transfer and comparability work were reported complete, and regulators had approved facility-produced material for ongoing and future clinical trials. Manufacturing qualification, supply, and regulatory execution remain risks.
- In August 2023, Replimune settled its patent dispute with Amgen, terminated its challenges to Amgen patents, and agreed to low-single-digit royalties on qualifying net sales where the license applies.
- The Hercules loan matures in October 2027 and bears floating cash interest subject to a 7.25% floor, plus 1.50% payment-in-kind interest. A covenant requiring minimum unrestricted cash begins January 1, 2024; additional financial tests may apply from the later of July 1, 2024 or when principal reaches $100 million.
- Key risks include clinical-trial failure or delay, regulatory uncertainty (including accelerated-approval requirements), dependence on collaborators and third-party supplies, manufacturing execution, competition, intellectual-property exposure, and the need for future financing. The filing reports no material legal proceedings. Management judged disclosure controls effective as of September 30, 2023.
Important facts for investors to verify
- Whether CERPASS and IGNYTE data supported the stated BLA timelines, and what regulators required for any application or confirmatory trial.
- Whether the cash runway assumptions remain valid as clinical, manufacturing, and pre-commercial spending rises; operating cash use was $92.2 million in the first half.
- Potential dilution from the $250 million ATM authorization, outstanding pre-funded warrants, options and restricted stock units. The filing reports 59.1 million issued shares, while weighted-average shares used for loss per share include warrant shares; confirm the applicable share-count basis.
- Future debt draw availability, interest expense, and compliance with Hercules cash and other financial covenants.
- The scope and potential financial impact of the Amgen royalty obligation and the progress, cost-sharing terms, and supply arrangements under clinical collaborations.